ArticleFrontiers in oncology2024

Clinical outcomes of atezolizumab versus standard-of-care docetaxel with and without ramucirumab in patients with advanced non-small-cell lung cancer who received prior immunotherapy.

Shenduo Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.